Regulatory FDA delays decision on Sanofi’s subcutaneous Sarclisa PharmaphorumThe FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.RegulatoryOncologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex. RegulatoryOncologyRead full story Post navigation Previous: MSD-backed Ray locks in $125m to back eye drug pipelineNext: Lilly exits Rigel alliance, adding to RIPK1 scrap heap Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026